First Tracks Biotherapeutics, Inc.: reports positive topline ANB033 data

What happened First Tracks Biotherapeutics, Inc. filed a Form 8-K on Oct 13, 2026 reporting that on Oct 12, 2026 it updated its corporate investor presentation and issued a press release announcing positive topline data from the first Phase 1b cohort of ANB033 in celiac disease.

Key details

• The Form 8-K was filed on Oct 13, 2026.
• On Oct 12, 2026 the company updated its corporate investor presentation (Regulation FD disclosure, Item 7.01).
• On Oct 12, 2026 the company issued a press release announcing positive topline data from the first Phase 1b cohort of ANB033 in celiac disease (Other events, Item 8.01).
• The press release was filed with the 8-K.

Why it may matter

• Item 7.01 reports a Regulation FD disclosure covering the updated corporate investor presentation.
• Item 8.01 reports an other event covering the press release announcing positive topline data from the first Phase 1b cohort of ANB033 in celiac disease.
  A filing does not show why the insider traded or why the company acted.